Assessing Participants’ Experiences with Vitiligo from Patient Interviews
Open Access
- 5 August 2024
- journal article
- research article
- Published by Springer Nature in Dermatology and Therapy
- Vol. 14 (9) , 2467-2478
Abstract
Introduction Vitiligo is an autoimmune disease, causing skin depigmentation. Individuals with vitiligo incur substantial psychosocial burden and have expressed frustration with their treatments. Here, we describe the burden of vitiligo and opinions on what constitutes meaningful change among participants of two qualitative interview studies. Methods Qualitative interviews were conducted with a subgroup of adolescent and adult participants with vitiligo from two pivotal phase 3 clinical trials of ruxolitinib cream (Study 1) and a real-world panel (Study 2). Participants were asked about their disease burden, treatment goals, importance of facial/body improvement (treatment satisfaction: scale range 0–10), and meaningfulness of change (yes/no). Results A total of 36 participants from Study 1 and 23 from Study 2 were interviewed. In Study 1, the highest degree of impact was on reduced self-esteem (facial lesions, 62.5%; body lesions, 55.6%), social inhibition (facial lesions, 65.6%; body lesions, 61.1%), and sun sensitivity (facial lesions, 31.3%; body lesions, 55.6%). Most participants (83.3%) reported that facial improvement was equally (36.1%) or more important (47.2%) than body improvement, with mean treatment satisfaction of 8.1 and 6.9, respectively. Meaningful change was reported by 83.3% and 92.9% of participants with 50–74% and ≥ 75% improvement per the facial Vitiligo Area Scoring Index, respectively, and by 82.6% of participants with ≥ 25% improvement per the total Vitiligo Area Scoring Index per Study 1 outcomes at Week 24. In Study 2, most (82.6%) participants felt that the noticeability of their vitiligo affected their behavior. Nearly all (87.0%) said that an ideal treatment would repigment or return natural color to their facial skin; 56.5% considered ≥ 50% facial repigmentation to be the smallest meaningful improvement. Conclusions Participants from both qualitative interviews expressed substantial psychosocial burden. Repigmentation in both facial and body vitiligo were important, with meaningful change determined to be ≥ 50% facial repigmentation and ≥ 25% body repigmentation.Keywords
Funding Information
- Incyte
This publication has 22 references indexed in Scilit:
- Facial involvement is reflective of patients’ global perception of vitiligo extentBritish Journal of Dermatology, 2023
- Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for VitiligoNew England Journal of Medicine, 2022
- A Qualitative Study to Develop and Evaluate the Content Validity of the Vitiligo Patient Priority Outcome (ViPPO) MeasuresDermatology and Therapy, 2022
- Meaningful Changes in What Matters to Individuals with Vitiligo: Content Validity and Meaningful Change Thresholds of the Vitiligo Area Scoring Index (VASI)Dermatology and Therapy, 2022
- Psychosocial Effects of Vitiligo: A Systematic Literature ReviewAmerican Journal of Clinical Dermatology, 2021
- Vitiligo: Patient stories, self-esteem, and the psychological burden of diseaseInternational Journal of Women's Dermatology, 2018
- Vitiligo and depression: a systematic review and meta‐analysis of observational studiesBritish Journal of Dermatology, 2017
- New discoveries in the pathogenesis and classification of vitiligoJournal of the American Academy of Dermatology, 2017
- Content Validity—Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product Evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 1—Eliciting Concepts for a New PRO InstrumentValue in Health, 2011
- Vitiligo: A comprehensive overviewJournal of the American Academy of Dermatology, 2011